Grant Avenue Capital has recapitalized CREO Inc.
The life sciences consulting industry is witnessing a dynamic shift as it adapts to emerging trends. With advancements in biotechnology, precision medicine, and data analytics, consulting firms are playing a pivotal role in guiding pharmaceutical, biotech, and healthcare companies towards innovation and market success. The complex regulatory landscape, coupled with the challenges of global expansion and pricing strategies, underscores the demand for specialized consulting expertise. A growing emphasis on patient-centricity, diversity in clinical trials, and environmental sustainability are shaping the industry’s trajectory. Life sciences consulting is not only a catalyst for change but also a key driver in advancing healthcare and pharmaceutical solutions reshaping the future.
Founded in 2015, CREO Inc. (“CREO”) is an award-winning provider of strategy, M&A, digital transformation, cyber security, IT quality and regulatory compliance consulting services to life sciences and healthcare organizations. CREO boasts an impressive history of delivering business results and expanding its customer base, exemplified by its consistent inclusion in the Inc. 5000 list of America’s fastest-growing private companies for the last four years and its recurrent recognition on the Triangle Business Journal’s Fast 50 list of rapidly growing companies in the Triangle region. CREO’s impressive capabilities and market leadership position made it the ideal strategic partner for Grant Avenue Capital to enhance the build out of its life sciences consulting platform.
Crosstree’s comprehensive knowledge of the life sciences consulting industry assisted Grant Avenue in evaluating CREO as the optimal partner through:
- Assessing the potential of strategic growth opportunities for CREO
- Developed a market information strategy to underwrite the recapitalization of CREO